'Novel' oral iron drug accepted for review in Europe
This article was originally published in Scrip
Executive Summary
Shield Therapeutics has had its European filing for a novel oral iron replacement drug accepted for review by the EMA. Feraccru (ST10, ferric maltol), for the treatment for iron deficiency anemia (IDA) in patients with inflammatory bowel disease (IBD) and those intolerant of oral ferrous therapies – has been developed as an alternative for those patients whose only current option is intravenous iron therapy.